艾曲莫德治疗中重度溃疡性结肠炎成人患者的观察性研究 (ENDEAVOUR-UC)
A MULTI-CENTER, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS (ENDEAVOUR-UC)
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod.
All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer.
The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Arizona
-
Mesa、Arizona、美国、85206
- Reddy GI Associates
-
-
California
-
La Jolla、California、美国、92037
- Scripps Clinic Torrey Pines
-
Los Alamitos、California、美国、90720
- United Medical Doctors
-
-
Colorado
-
Littleton、Colorado、美国、80120
- Rocky Mountain Gastroenterology
-
-
Florida
-
Kissimmee、Florida、美国、34741
- Digestive and Liver Center of Florida Kissimmee
-
Lutz、Florida、美国、33558
- Gastro Florida
-
Orlando、Florida、美国、32806
- Orlando Health/Digestive Health Institute
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Rush University Medical Center
-
Chicago、Illinois、美国、60611
- Feinberg School of Medicine Northwestern University
-
Naperville、Illinois、美国、60540
- Suburban Gastroenterology Ltd
-
-
Maryland
-
Chevy Chase、Maryland、美国、20815
- MGG Group Co., Inc., Chevy Chase Clinical Research
-
Glen Burnie、Maryland、美国、21061
- Woodholme Gastroenterology Associates PA
-
-
New Jersey
-
Marlton、New Jersey、美国、08053
- Virtua Health
-
-
New York
-
New York、New York、美国、10016
- NYU Langone Health
-
New York、New York、美国、10075
- Lenox Hill Hospital, Northwell Health
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology
-
Charlotte、North Carolina、美国、28211
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cincinnati、Ohio、美国、45267
- University of Cincinnati College of Medicine
-
Westlake、Ohio、美国、44145
- Gastro Intestinal Research Institute of Northern Ohio, LLC
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina (MUSC)
-
-
Texas
-
Houston、Texas、美国、77084
- BI Research Center
-
Houston、Texas、美国、77079
- Houston Endoscopy & Research Center
-
San Antonio、Texas、美国、78234
- Brooke Army Medical center
-
Southlake、Texas、美国、76092
- GI Alliance Research
-
-
Washington
-
Tacoma、Washington、美国、98405
- Washington Gastroenterology
-
-
West Virginia
-
Morgantown、West Virginia、美国、26505
- WVU Medicine J.W Ruby Memorial Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the United States etrasimod prescribing information and independent from the decision to enroll the patient in this study.
描述
Inclusion Criteria:
- Age ≥ 18 years and < 65 years at baseline
- Patients with confirmed diagnosis of UC who are prescribed etrasimod for moderately to severely active UC
- Evidence of a personally signed and dated ICD indicating that the patient (or a legally acceptable representative)has been informed of all pertinent aspects of the study
Exclusion Criteria:
-
The presence of clinical findings suggestive of Crohn's disease
-
Severe extensive colitis evidenced by:
- Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (e.g., colectomy) within 12 weeks
- Current evidence of acute severe UC, fulminant colitis, or toxic megacolon
-
Patients with a stoma or planned UC surgical intervention requiring hospitalization
-
Prior/Concomitant Therapy:
- Any previous exposure to etrasimod, including participation in the etrasimod clinical program
- Any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine, or tioguanine)
- Any co-medication with one of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist; JAKi [filgotinib, tofacitinib, or upadacitinib]) or with any other S1P receptor modulator
-
Unwillingness or inability to download the web-based tool to complete ePROs on a personal device or not capable of using the web-based tool
-
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
服用依曲莫德的成人溃疡性结肠炎患者
|
As provided in real world practice |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with symptomatic remission
大体时间:Week 12
|
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0 |
Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with symptomatic remission
大体时间:Weeks 24, 36, 52
|
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0 |
Weeks 24, 36, 52
|
|
Proportion of patients with symptomatic response
大体时间:Weeks 12, 24, 36, 52
|
Symptomatic response defined as a decrease from baseline ≥ 30% in pMMS composite RBS and SFS |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with symptomatic response
大体时间:Weeks 12, 24, 36, 52
|
Symptomatic response defined as a decrease from baseline ≥ 20% in pMMS composite RBS and SFS |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with clinical remission
大体时间:Weeks 12, 24, 36, 52
|
Clinical remission is defined as a pMMS ≤ 2 points, with no individual subscores > 1 point. |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with steroid-free symptomatic remission (among all patients and among patients in symptomatic remission)
大体时间:Weeks 24, 36, 52
|
Steroid-free symptomatic remission is defined as patients in symptomatic remission who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint |
Weeks 24, 36, 52
|
|
Proportion of patients with steroid-free clinical remission (among all patients and among patients in clinical remission)
大体时间:Weeks 24, 36, 52
|
Steroid-free clinical remission is defined as patients in clinical remission (using a pMMS) who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint |
Weeks 24, 36, 52
|
|
Change from baseline in fatigue
大体时间:Weeks 12, 24, 36, 52
|
Change from baseline in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score Normalization of fatigue is defined as a FACIT Fatigue score ≥ 40.1 |
Weeks 12, 24, 36, 52
|
|
Change from baseline of bowel urgency
大体时间:Weeks 12, 24, 36, 52
|
Change from baseline in bowel urgency on a 0 (no urgency) - 10 (worst possible urgency) numeric rating scale |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with a clinically meaningful improvement in bowel urgency
大体时间:Weeks 12, 24, 36, 52
|
Clinically meaningful improvement in bowel urgency is defined as ≥ 3-point decrease from baseline among patients with baseline bowel urgency score ≥ 3 |
Weeks 12, 24, 36, 52
|
|
Proportion of patients in bowel urgency remission
大体时间:Weeks 12, 24, 36, 52
|
Bowel urgency remission is defined as a bowel urgency score ≤ 1 among patients with a baseline bowel urgency score ≥ 3 and the overall population |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with complete bowel urgency remission
大体时间:Weeks 12, 24, 36, 52
|
Complete bowel urgency remission is defined as a bowel urgency Numeric Rating Scale score = 0 |
Weeks 12, 24, 36, 52
|
|
Change from baseline in abdominal pain
大体时间:Weeks 12, 24, 36, 52
|
Change from baseline in abdominal pain on a 0 (no pain) - 10 (pain as bad as can imagine) numeric rating scale |
Weeks 12, 24, 36, 52
|
|
Proportion of patients with abdominal pain remission
大体时间:Weeks 12, 24, 36, 52
|
Abdominal pain remission is defined as an abdominal pain Numeric Rating Scale score = 0 |
Weeks 12, 24, 36, 52
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- C5041047
- ENDEAVOUR-UC (其他标识符:Alias Study Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.